Lazard Capital Initiates Coverage on AmerisourceBergen (ABC) with a Buy
More News related to ABC
- AmeriSourceBergen (ABC) Beats Q4 Views by 4c; Guides FY10
- AmerisourceBergen Reports $0.44 Diluted EPS, Up 22 Percent, and Record Revenue, Up 9 Percent, in the September Quarter
- Trading Radar for 11/03: UBS (UBS), Yamana Gold (AUY), Archer-Daniels (ADM), Royal Caribbean (RCL), Marathon (MRO) Report
- BioInformatics, LLC New Report - The Market Outlook for Research Products in FY2010
- AmerisourceBergen Announces Date and Time for Fourth Quarter and Fiscal Year End Earnings Release
More News related to New Coverage
- Janney Montgomery Scott Upgrades Ameristar Casinos (ASCA) to Buy; Favorable Risk/Reward
- Goldman Sachs Upgrades Adobe Systems (ADBE) to Buy
- Goldman Sachs Upgrades SandRidge Energy (SD) to Neutral
- Keefe, Bruyette & Woods Upgrades Blackstone Group (BX) to Outperform
- Wells Fargo Upgrades Macquarie Infrastructure (MIC) to Outperform; Raises Valuation Range
Lazard Capital initiates coverage on AmerisourceBergen (NYSE: ABC) with a Buy. Price target $22.
To see more analyst ratings on ABC Click Here.
AmerisourceBergen Corporation (AmerisourceBergen) is a pharmaceutical services company, with operations in the United States, Canada and the United Kingdom.
Related Categories
New CoverageStocks Mentioned
+0.00Related Entities
Sign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
